Duplicate Document
This document appears to be a copy. The original version is:
FDA editorial on breakthrough therapy designation and investment fund strategyFDA editorial on breakthrough therapy designation and investment fund strategy
FDA editorial on breakthrough therapy designation and investment fund strategy The passage is a routine editorial describing FDA policy and a private investment fund's focus. It contains no allegations, financial misconduct, or links to high‑profile officials beyond standard titles, offering no actionable investigative leads. Key insights: Janet Woodcock, MD, FDA CDRH director, co‑authored a NEJM editorial on breakthrough therapy designation.; Breakthrough therapy designation created under FDASIA in 2012; 26 designations granted on 80 requests as of 2013.; Discussion of biotech investment strategy (NLV‑III fund) focusing on information convergence and healthcare cost reduction.
Summary
FDA editorial on breakthrough therapy designation and investment fund strategy The passage is a routine editorial describing FDA policy and a private investment fund's focus. It contains no allegations, financial misconduct, or links to high‑profile officials beyond standard titles, offering no actionable investigative leads. Key insights: Janet Woodcock, MD, FDA CDRH director, co‑authored a NEJM editorial on breakthrough therapy designation.; Breakthrough therapy designation created under FDASIA in 2012; 26 designations granted on 80 requests as of 2013.; Discussion of biotech investment strategy (NLV‑III fund) focusing on information convergence and healthcare cost reduction.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.